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Introduction: Hemophilia A is an X linked recessive hemorrhagic disorder caused by mutations in the F8 gene
that lead to qualitative and/or quantitative deficiencies of coagulation factor VIII (FVIII). Molecular diagnosis of
hemophilia A is challenging because of the high number of different causative mutations that are distributed
throughout the large F8 gene. Molecular studies of these mutations are essential in order to reinforce our
understanding of their pathogenic effect responsible for the disorder.
Aim: In this study we have performed molecular analysis of 28 Tunisian hemophilia A patients and analyzed the
F8 mutation spectrum.
Methods: We screened the presence of intron 22 and intron 1 inversion in severe hemophilia A patients
by southern blotting and polymerase chain reaction (PCR). Detection of point mutations was performed by
dHPLC/sequencing of the coding F8 gene region. We predict the potential functional consequences of novel
missense mutations with bioinformatics approaches and mapping of their spatial positions on the available
FVIII 3D structure.
Results: We identified 23 different mutations in 28 Tunisian hemophilia A patients belonging to 22 unrelated
families. The identified mutations included 5 intron 22 inversions, 7 insertions, 4 deletions and 7 substitutions.
In total 18 point mutations were identified, of which 9 are located in exon 14, the most mutated exonic
sequence in the F8 gene. Among the 23 mutations, 8 are novel and not deposited in the HAMSTeRS database
nor described in recently published articles.
Conclusion: The mutation spectrum of Tunisian hemophilia A patients is heterogeneous with the presence
of some characteristic features.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1693269827490715
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Figure 1 Distribution of Tunisian hemophiliacs A according to
their severity.
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Hemophilia A is an X linked hereditary bleeding dis-
order which results from a deficiency or abnormality in
FVIII activity. The FVIII protein is composed of struc-
tural domains represented as A1-A2-B-A3-C1-C2 and is
activated after the dissociation of the B domain. A large
and heterogeneous spectrum of mutations has been
identified in the F8 gene [1]. They include partial or
complete gene deletions, duplications, large insertions,
splice alteration, frameshifts as well as nonsense and
missense mutations (FVIII mutation database: http://
hadb.org.uk). The most common mutations in severe
hemophilia A are the intron 22 inversion mutations
which occur in 45-50% of severe hemophilia A patients
and the intron 1 inversion mutation which has been
reported to be present in approximately 5% of patients
with severe phenotypes [2,3]. The development of inhibi-
tors in patients presents a major complication of treat-
ment with FVIII, especially in patients with severe forms
of hemophilia A [4]. The Hemophilia treatment centre
of Aziza Othmana Hospital in Tunisia follows 143
hemophilia A patients. 72 of these patients have been
diagnosed with severe, 49 with moderate and 22 with
mild hemophilia A.
In a previous study we have determined the haplotype
frequency in Tunisian hemophiliacs A concerning only
single nucleotide polymorphisms (SNPs) [5]. Our aim in
this study has been to identify the molecular genetics of
hemophilia A patients for the first time in Tunisia. The
characterization, molecular analysis and spectrum of
these genetic alterations are reported in this paper.
Patients and methods
Patients
28 patients with hemophilia A from 22 unrelated fam-
ilies were included in this study. At the time of the study
their age ranged between 4 to 38 years. 19 patients had
severe form, 5 had moderate form and 4 had mild form
of hemophilia A (Figure 1). All the patients gave
informed consent for molecular studies.
Molecular genetic analysis
DNA was extracted from whole blood samples using a
phenol chloroform protocol. Severe hemophilia A patients
were first screened for intron 22 inversion. Negative
patients were then tested for intron 1 inversion. Intron 22
inversion was detected using LD PCR and confirmed
with southern blot as described [6]. Intron 1 inversion
was performed using the Bagnall’s protocol [7].
PCR amplification was performed for mild, moderate
and severe hemophilia A patients without intron 22 or
intron 1 inversions. The coding sequence of F8 gene was
divided into 33 amplicons (200-480 bp). Exon 14 was
divided into 8 fragments for PCR amplification and theother exons were amplified as unique fragments. Primer
sequences, annealing temperatures and the size of PCR
fragments are available from the corresponding author,
on request. Mixtures of patients and wild type DNA
were screened by denaturing high liquid performance
(dHPLC) on a WAVE DNA Fragment Analysis System
(Transgenomics, San Jose, USA). All large deletions were
defined as a consistent absence of PCR amplification
products. Altered profile revealed by dHPLC were then
sequenced in both strands using ABI Dye Terminator
Cycle Sequencing (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA) and analyzed using a capillary
sequencer Genetic Analyser ABI PRISM310 (Perkin-
Elmer Applied Biosystems, Foster City, CA, USA). Muta-
tions were confirmed by a second PCR and sequencing.
Results were analyzed using BLAST (www.ncbi.nlm. nih.
gov/blast) program in comparison with the wild-type
F8 gene sequence. Mutation nomenclature was given
according to HAMSTeRS as well as in parentheses
according to the international recommendations for the
description of sequence variants on the Human Genome
Variation Society (HGVS) website (http://www.hgvs.org).
Analysis of missense mutations
All identified F8 mutations were compared to those
described in the HAMSTeRS database (http://www.
HAMSTeRS.ac.uk/). PolyPhen software (Polymorphism
Phenotyping) was used to perform the sequence align-
ment of the homologous FVIII from four mammalian
species (human, murine, canine and pig) and to predict
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structure and function of FVIII. The 3D structure of
FVIII was visualized using the PyMOL Molecular
Graphics System (http://www.pymol.org) [8].Family 8 1 <1% Yes : 18 kb,
15.5 kb and 14 kb
Family 9 2 <1% Yes
Family 10 1 <1% Yes
Family 11 2 <1% yes
Family 12 1 <1% yesResult
In this study, 28 hemophilia A patients from 22 unre-
lated families were investigated. In total we identified
23 different mutations, which included 5 intron 22
inversions, 8 substitutions, 6 insertions and 4 deletions
identified in 4 severe hemophilia A patients (Figure 2,
Tables 1 and 2). Among the 23 different mutations, 8
are novel mutations and have not been described in
HAMSTeRS database or reported in recently pub-
lished data. Of these novel mutations, 6 occur in se-
vere hemophilia A patients (del exons 1–13, intron 22
inversion (18 kb, 15.5 kb and 14 kb), p.1595(1614)
DfsX40, p.12(31)LfsX11, p.C179(198)R and p.N784
(803)N) and 2 occur in moderate hemophilia A
patients (p.727(746)SfsX7 and p.G520(539)R).
Analysis of the two novel missense mutations p.C179
(198)R and p.G520(539)R using the PolyPhen Software
suggested both mutations to be considered as structur-
ally damaging. Further analysis, mapping the substitu-
tion sites on the 3D structure of FVIII, show that both
of these mutated residues are involved in interaction that
can be considered important for the structural integrity
of the mature FVIII protein. Residue C179(198) forms a
disulfide bond with the residue C153. The mutation p.
C179(198)R disrupts this disulfide bond formation, and
thereby most likely leads to destabilization of the A1Figure 2 Frequencies of identified mutations according to
their types.domain (Figure 3). The second novel mutation p.G520
(539)R is located in the interface between the A1 and A2
domains. Substitution of this neutral glycine with a
charged arginine probably disturbs the interactions in
this interface and destabilizes the interaction between
the A1 and A2 domains (Figure 3).
Discussion
We report the first molecular study performed in Tunisian
hemophilia A patients belonging to Hemophilia Treat-
ment Center of Aziza Othman Hospital. Our cohort
consists of 28 patients from 22 unrelated families. Des-
pite the limited number of our cohort, the novel muta-
tions occur with a significant frequency (34%) indicating
that our patients have a specific mutational profile in
comparison with previously reported data. Each studied
family was found to have its unique mutation except for
one. Among the 18 identified point mutations 9 were
located in exon 14, the largest exonic coding sequence
of the F8 gene. The correlation between genotype/
phenotype was assessed for the identified mutations in
order to clarify the effect of mutations on the phenotype
and to compare our data with previously reported data.
Severe hemophilia A patients
Inversions (5)
In the 19 patients with severe hemophilia A, intron 22
inversion was identified in 7 patients (36.84%) belong-
ing to five different families, while no family present
intron 1 inversion (0%). This result indicates that
the intron 22 inversion, which is reported in severe
hemophilia A in the general population with a frequency
of 45%-50% [9], is less frequent in our patient cohort.
The same tendency was found for the intron 1 inversion,
which is reported with a frequency of 5% [10]. When we
compare our findings with previous data from other
Arab countries the frequencies of these 2 inversions are
lower in our patients [11-14]. This result shows that
our patients have a specific genetic profile which is
confirmed by other molecular studies concerning our
country [15]. Nevertheless, this data must be confirmed
with a larger number of studied patients.
Table 2 Identified causative mutations in Tunisian hemophiliacs A
Family Number
of Patient
FVIII:C Severity Mutation Type Location Domain Inhibitors Reported
Family 1 1 <1% Severe c.90-91insA; p.12(31)LfsX11 Insertion Exon 1 A1 No Novel
Family 2 1 5% Moderate c.1615 G>C; p.G520(539)R Missense Exon 11 A2 No Novel
Family 3 1 2.5% Moderate ag/GGC>ac/GGC Splicing Intron14 B No Reported
Family 4 1 <1% Severe Exons1-13del Large deletion Exons 1-13 A1-A2 Yes Novel
Family 5 1 <1% Severe c.592 T>C; p.C179(198)R Missense Exon 4 A1 No Novel
Family 6 2 <1% Severe c.4844ins264pb Large insertion Exon 14 A1 No Novel
Family 7 1 12.5% Moderate c.2236-2237insT; p.727(746)SfsX7 Insertion Exon 14 B No Novel
Family 11 2 <1% Severe c.3637-3638insA; p.1191(1210)IfsX29 Insertion Exon 14 B No Reported
Family 13 1 <1% Severe c.4379-4380insA; p.1441(1460)KfsX2 Insertion Exon 14 B No Reported
Family 14 1 <1% Severe c.6873-6876delTC; p.2272(2291)TfsX Deletion Exon 25 C2 No Reported
Family 15 1 <1% Severe c.3637-3638delA; p.1191(1210)IfsX5 Deletion Exon 14 B No Reported
Family 16 1 <1% Severe c.5071-5075delATGAA; p.1671-3(1690–3)fsX Deletion Exon 14 B No Reported
Family 17 2 <1% Severe c.77 T>C; p.L7(26)P Missense Exon 1 A1 No Reported
Family 18 1 4.4% Moderate c.1492 G>A; p.G479(498)R Missense Exon 10 A2 No Reported
Family 19 1 6.5% Mild c.1696 C>T; p.L547(566)F Missense Exon 11 A2 No Reported
Family 20 1 1.6% Moderate c.3870-3871insA; p.1271(1290)KfsX29 Insertion Exon 14 B No Reported
Family 21 3 12-20% Mild c.2167 G>A; p. A704(723)T Missense Exon 14 B No Reported
Family 22 1 <1% Severe c.2409 T>C; p.N784(803)N Missense Exon 14 B No Novel
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type I inversion was the most frequent in our patients
(families 10, 11 and 12), which correlates with what pre-
viously has been reported in the literature [16]. The type
II inversion was identified in one patient (family 9) and aFigure 3 (A) Crystal structure of B domain-deleted factor VIII (PDB ID
The positions of the mutations studied in this article are indicated by arrow
and nearby residues shown as stick models and hydrogen bonds as dashe
between the A1 and A2 domains and (C) the p.C179(198)R mutation locatenovel atypical pattern (family 8) with 3 bands (18 kb,
15.5 kb and 14 kb), since the amplification of exons 22
and 23 gave the expected size this atypical pattern may
be explained by a deletion of 2 kb in the INT22-h1 or in
the INT22-h3 homologous regions (Table 1).2R7E). The domains are individually labeled and in different colors.
s. Close-up views of the positions of the mutations with the mutated
d lines. (B) The p.G520(539)R mutation located in the interface
d in A2 domain.
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In our cohort of severe patients we identified 7 frame-
shift mutations (Table 2). All of them are associated with
very low or undetectable FVIII:C in plasma leading to a
severe phenotype as expected, since frameshift muta-
tions resulting from insertions or/deletions in most cases
lead to severe phenotypes [17]. The new large deletion
spanning exons 1-13 was found in one patient with
severe hemophilia A and was associated with develop-
ment of inhibitors (family 4).
Substitutions (3)
We identified 3 substitutions in 3 unrelated families with
severe hemophilia A (Table 2), among these the novel
mutation p.C179(198)R, which occurs in exon 4 within
the A1 domain (family 5). In the encoded protein this
mutation substitutes a conserved cystein residue and
disrupts the disulfide bond formation leading to
destabilization of the A1 domain. The severe phenotype
associated with this mutation is in accordance with pre-
viously reported genotype/phenotype correlation. For
instance, the mutation p.C179(189)G, which is also asso-
ciated with a severe phenotype, is reported twice in
HAMSTeRS [18]. Previous studies have also highlighted
that mutations of conserved amino acids in FVIII fre-
quently are associated with a severe phenotype [19,20].
The second novel mutation, p.N784(803)N, is a
silent mutation identified in one patient with severe
hemophilia A (family 22). This silent mutation has no
effect on the mature FVIII protein structure, but it
might play a role in the expression levels of the pro-
tein, such as other silent mutations which have been
recently identified [21]. To confirm this hypothesis we
need to screen this point mutation in healthy indivi-
duals in order to exclude that it is not associated with
a SNP, since it is not reported in the HAMSTeRS
data base or in recent identified SNPs [22]. The exact
effect of this mutation remains elusive and will be of
interest for future studies to reveal. The finding that
the mutation p.L7(26)P identified in family 17 is asso-
ciated with a severe phenotype is in accordance with
previous findings, which have shown that the same
mutation causes a severe phenotype [23].
Inhibitor development
The type and location of the F8 gene mutation is an
important determinant of inhibitor development in
patients with severe hemophilia A. In a recent study,
nonsense mutations and large deletions were shown to
be associated with a higher risk of inhibitor development
than intron 22 inversion, small deletions/insertions and
missense mutations [24]. In our cohort no nonsense
mutation was identified and only one patient with a
large deletion spanning the exons 1–13 developedinhibitors. None of the patients with insertions/small
deletions or missense mutations developed inhibitors.
The low incidence of inhibitor development in our
cohort (1/28) and (6/143) in total for all patients fol-
lowed in Hemophilia Treatment Center [25] may be
explained by the low frequency of nonsense mutations
and large deletions in our cohort. In order to confirm
this hypothesis we need to increase the number of the
investigated hemophilia A patients in our study.
Moderate hemophilia A patients
Insertions (2)
The novel insertion c.2236-2237insT and the previously
reported insertion c.3870-3871insA identified in family 7
and 20 respectively (Table 2), are due to insertions of a
‘T’ nucleotide in the stretch of 3Ts at codon 727(746)
and of an ‘A’ nucleotide in the stretch of 9As at
codon1271(1290). Insertions in the stretch of poly A
nucleotides in exon 14 of the F8 gene are the cause of
the moderate clinical severity in some cases [26,27]. Ac-
cordingly to these reported data, we can consider that
also the new insertion of T in the stretches of poly T can
be associated with moderate phenotype in our patient.
Substitutions and splicing site mutations (3)
The novel p.G520(539)R mutation associated with the
moderate phenotype is located within the A1 domain
and is part of the A1-A2 domain interface. Reported
mutations in HAMSTeRS from position 516(525) to 521
(540) located at A1-A2 interface are all associated with
moderate or mild phenotypes http://www.HAMSTeRS.
ac.uk/, [28]. Studies of residues involved in interaction at
the A1-A2 domain interface have showed that reducing
the charge and increasing hydrophobicity at this inter-
face yield FVIII with improved stability [29,30]. Thus,
the mutation p.G520(539)R, which increases the charge
at the A1-A2 interface, most likely has the opposite
effect and leads to destabilization of the protein. The
reported missense mutation p.G479(488)R, which is
associated with a moderate phenotype in our patients, is
described in HAMSTeRS with mild moderate or severe
form [20]. The splicing site mutations are often asso-
ciated with a severe phenotype [31]. In contrast, the
unique identified splicing mutation (ag/GGC> ac/GGC)
in our study, which interferes in the splicing process
resulting in the skipping of exon 15, is associated with a
moderate phenotype (Table 2).
Mild hemophilia A patients
Substitutions (2)
The mutation p.A704(723)T is reported 9 times in the
HAMSTeRS data base, in 5 cases it is associated with
the mild form which is in accordance with our result
(Table 2). On the other hand the p.L547(566)F has
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our study it is associated with a mild form (Table 2). The
discrepancy between mutations predicted to be respon-
sible for severe, mild or moderate forms may be explained
by the intervention of other hemostatic factors which can
modify the clinical severity of hemophilia [32].
Conclusion
We report here the first molecular analysis of causative
mutations in Tunisian hemophiliac A patients. In total
we have identified 23 mutations including 8 novel muta-
tions. In the future we will continue this study on
patients from our Hemophilia Treatment Center in
order to reinforce our understanding in the molecular
defect of hemophilia A in Tunisia and to set up counsel-
ing genetic and the prenatal diagnosis for Tunisian fam-
ilies with hemophilia A.
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